Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Anne Stidholt Roug"'
Autor:
Maria Nascimento Primo, Emil Aagaard Thomsen, Xiaohong Tan, Ditte Starberg Jespersen, Anna Amanda Schönherz, Laura Barrett Ryø, Hanne Due, Martin Bøgsted, Karen Dybkær, Jacob Giehm Mikkelsen, Yuyang Pang, Anne Stidholt Roug, Ken H. Young, Min Xiao
Publikováno v:
Due, H, Schönherz, A A, Ryø, L, Primo, M N, Jespersen, D S, Thomsen, E A, Roug, A S, Xiao, M, Tan, X, Pang, Y, Young, K H, Bøgsted, M, Mikkelsen, J G & Dybkær, K 2019, ' MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma ', Blood advances, vol. 3, no. 7, pp. 1185-1196 . https://doi.org/10.1182/bloodadvances.2018029660
Due, H, Schönherz, A A, Ryø, L, Primo, M N, Jespersen, D S, Thomsen, E A, Roug, A S, Xiao, M, Tan, X, Pang, Y, Young, K H, Bøgsted, M, Mikkelsen, J G & Dybkær, K 2019, ' MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma ', Blood Advances, vol. 3, no. 7, pp. 1185-1196 . https://doi.org/10.1182/bloodadvances.2018029660
Due, H, Schönherz, A A, Ryø, L, Primo, M N, Jespersen, D S, Thomsen, E A, Roug, A S, Xiao, M, Tan, X, Pang, Y, Young, K H, Bøgsted, M, Mikkelsen, J G & Dybkær, K 2019, ' MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma ', Blood Advances, vol. 3, no. 7, pp. 1185-1196 . https://doi.org/10.1182/bloodadvances.2018029660
A major clinical challenge of diffuse large B-cell lymphoma (DLBCL) is that up to 40% of patients have refractory disease or relapse after initial response to therapy as a result of drug-specific molecular resistance. The purpose of the present study